



Advantx Pharmaceuticals Selected to Present it's World-Class Sigma Platform at PAINWeek

September 05, 2023 — (New York, NY) Advantx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing advanced disease-modifying therapies based on Sigma receptors, announced today that it has been selected to present at the prestigious PAINWeek conference, September 5th-8th in Las Vegas. This will be the company's first time showcasing their platform to the U.S. Conference Community, after presenting at Roma Pain Days in Italy and other various conferences in Mexico and Tunisia.

"Recent data has highlighted the need for alternative treatments to manage opioid use disorder and poly substance use disorder, ADV502 is a promising new chemical entity, designed to specifically provide a multi mechanistic therapeutic option," stated the company's President and CEO, Dr. Joseph Pergolizzi.

"The Sigma receptor has been an enigma in pharmacology for many decades," Chief Scientist for Advantx, Dr. Robert Raffa added. "But it has recently been discovered to be a ligand-sensitive chaperone protein. Based on this new understanding, Advantx has developed small-molecule Sigma-targeted ligands, including the dual-acting ADV502. In its mechanism-of-action novelty is the promise of exciting clinical potential."

PAINWeek is celebrating its 17th annual conference at and remains one of the most expansive US pain conferences for frontline practitioners providing over a 1,000+ hours of educational content. The following Advantx abstracts will be available online via the PAINWeek and the company's websites, and the corresponding scientific posters will be displayed in the exhibit hall at The Cosmopolitan of Las Vegas from Sept. 5-8, 2023:

- Sigma Receptor Redux (#PW15523)
- Sigma-1 and Sigma-2 Chaperone-Receptors for Therapeutic Targets (#PW15623)
- ADV502: Possible Role for Maintenance treatment of (Poly)Substance Use Disorder (#PW15723)

About Advantx Pharmaceuticals Inc.

Advantx Pharmaceuticals is a New York-based clinical-stage biopharmaceutical company dedicated to developing advanced disease-modifying therapies based on Sigma receptors. Having developed a proprietary platform of advanced pharmaceutical-grade compounds that selectively modulate the unique ligand-operated chaperones proteins encoded by the SIGMAR1 and TMEM97/SIGMAR2 genes, as well as other essential proteins related to their respective pathways, the company's comprehensive pipeline of novel chemical structures allows them to modulate multiple disease-causing pathways while normalizing the homeostasis of key proteins and cells under stress or DNA damage. Please visit www.Advantx.org for more information.

###

Advantx Media Contact:

Morgan Wagner
Media & Investor Relations
Morgan@advantx.org